CareDx commemorates the life of James “Jim” Gleason, a selfless leader, patient advocate, heart transplant recipient and longtime President of the Transplant Recipients International Organization (TRIO), who died on August 26, 2022, after battling incurable pancreatic cancer. Jim spent the last few days of his life the same way he lived his life, by being a friend and patient advocate, while also working tirelessly to ensure that his organization’s important work for the transplant community would remain unabated. Meanwhile, he remained accessible to his inner circle of family, friends, industry partners, patients, and donor families. Read more at CareDx.com.
PTC: Cancer Risks for Kidney Recipients
WHY AM I AT GREATER RISK OF DEVELOPING CANCER AFTER KIDNEY TRANSPLANT?
“All organ transplant recipients are at heightened risk of developing cancer after transplant. This is because although life-sustaining, long-term use of immunosuppressant drugs lowers the body’s ability to fend off certain cancers. When you are taking immunosuppressant drugs, your immune response is lowered, and this is what helps to prevent your body from rejecting your new kidney. It also means that your body is less able to recognize and destroy cancer cells or infections that can cause cancer.”
Read more on TRIO’s new Post-transplant Cancer Project (PTC) website, here.
President of TRIO Discusses Transplantation Experience in Time of COVID-19
“Jim Gleason, National President of Transplant Recipients International Organization (TRIO), discusses what organ transplant patients are experiencing during the pandemic, and some tips they ought to consider to help ease some of the burden.
Mr. Gleason also discusses his role in the development of the recently released AlloCare app is in the AppStore, to help post-transplant recipients navigate their day-to-day health.”
Read the full interview here.